SEC Form 4/A · accession 0001567619-19-001261
Loxo Oncology, Inc. · LOXO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Joshua H. Bilenker
Officer — President & CEO · Director
Period of report
Jul 9, 2018
Accepted (ET)
Jan 17, 2019 · 8:06 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 9, 2018 | M | 7,500 | $1.184 | A | 141,207 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F2This amended Form 4 is being filed solely to correct the reporting person's ending balance by subtracting the additional 1,700 shares of the Issuer's common stock (the "Additional Shares") that were added inadvertently to the total number of shares held directly by the reporting person. The Additional Shares were included in all the subsequent directly held transactions in the Form 4 filed on July 11, 2018 and the five Forms 4 filed thereafter. As of January 17, 2019, the reporting person directly holds a total number of 162,707 shares of the Issuer's common stock.